Luis Jara-Palomares

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4370982/publications.pdf

Version: 2024-02-01

144 papers 2,868 citations

236925 25 h-index 48 g-index

154 all docs

154 docs citations

154 times ranked 2946 citing authors

#	Article	IF	Citations
1	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncology, The, 2019, 20, e566-e581.	10.7	458
2	Trends in the Management and Outcomes of Acute Pulmonary Embolism. Journal of the American College of Cardiology, 2016, 67, 162-170.	2.8	271
3	2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncology, The, 2022, 23, e334-e347.	10.7	138
4	Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study. Thrombosis Research, 2017, 157, 90-96.	1.7	105
5	Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2017, 167, 410.	3.9	96
6	The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site. American Journal of Medicine, 2017, 130, 337-347.	1.5	83
7	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. European Heart Journal, 2022, 43,	2.2	83
8	Consenso nacional sobre el diagnóstico, estratificación de riesgo y tratamiento de los pacientes con tromboembolia pulmonar. Archivos De Bronconeumologia, 2013, 49, 534-547.	0.8	70
9	Short-term clinical outcome of normotensive patients with acute PE and high plasma lactate. Thorax, 2015, 70, 333-338.	5.6	55
10	Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. Chest, 2017, 151, 564-571.	0.8	51
11	Normativa sobre el manejo de las complicaciones respiratorias de los pacientes con enfermedad neuromuscular. Archivos De Bronconeumologia, 2013, 49, 306-313.	0.8	48
12	Echocardiographic assessment of pulmonary arterial pressure in the follow-up of patients with pulmonary embolism. Thrombosis Research, 2011, 127, 303-308.	1.7	45
13	Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism. American Journal of Medicine, 2017, 130, 588-595.	1.5	45
14	Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism. Thrombosis Research, 2013, 132, 175-179.	1.7	44
15	Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism. Medicine (United States), 2015, 94, e1235.	1.0	43
16	Bleeding risk in hospitalized patients with COVIDâ€19 receiving intermediate―or therapeutic doses of thromboprophylaxis. Journal of Thrombosis and Haemostasis, 2021, 19, 1981-1989.	3.8	42
17	Hospital volume and outcomes for acute pulmonary embolism: multinational population based cohort study. BMJ: British Medical Journal, 2019, 366, 14416.	2.3	41
18	D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis. British Journal of Cancer, 2018, 119, 915-921.	6.4	37

#	Article	IF	Citations
19	Management appropriateness and outcomes of patients with acute pulmonary embolism. European Respiratory Journal, 2018, 51, 1800445.	6.7	33
20	Impact of sex, age, and risk factors for venous thromboembolism on the initial presentation of first isolated symptomatic acute deep vein thrombosis. Thrombosis Research, 2019, 173, 166-171.	1.7	32
21	Early Use of Echocardiography in Patients With Acute Pulmonary Embolism: Findings From the RIETE Registry. Journal of the American Heart Association, 2018, 7, e009042.	3.7	31
22	Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score. European Respiratory Journal, 2020, 56, 2002336.	6.7	30
23	CO306: Rivaroxaban for Treatment of Venous Thromboembolism. A Real-Life Perspective in 103 Patients. Thrombosis Research, 2014, 133, S41.	1.7	29
24	A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients withÂcatheter-related thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2015, 3, 243-250.e1.	1.6	28
25	Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation. JAMA - Journal of the American Medical Association, 2021, 326, 1277.	7.4	28
26	Noninvasive ventilation for severely acidotic patients in respiratory intermediate care units. BMC Pulmonary Medicine, 2016 , 16 , 97 .	2.0	27
27	Frequency and prognostic impact of acute kidney injury in patients with acute pulmonary embolism. Data from the RIETE registry. International Journal of Cardiology, 2019, 291, 121-126.	1.7	27
28	Utility of high-resolution computed tomography and BAL in cryptogenic organizing pneumonia. Respiratory Medicine, 2010, 104, 1706-1711.	2.9	26
29	Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism. Research and Practice in Thrombosis and Haemostasis, 2017 , 1 , 172 - 179 .	2.3	26
30	DVT Management andÂOutcome Trends, 2001 to 2014. Chest, 2016, 150, 374-383.	0.8	23
31	Testing for occult cancer in patients with pulmonary embolism: Results from a screening program and a two-year follow-up survey. Thrombosis Research, 2010, 125, 29-33.	1.7	22
32	Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score. Journal of Thrombosis and Haemostasis, 2017, 15, 2184-2187.	3.8	22
33	Extended anticoagulation treatment for cancerâ€associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review. Journal of Thrombosis and Haemostasis, 2022, 20, 619-634.	3.8	22
34	A Case-Control Analysis of the Impact of Venous Thromboembolic Disease on Quality of Life of Patients with Cancer: Quality of Life in Cancer (Qca) Study. Cancers, 2020, 12, 75.	3.7	20
35	Fondaparinux in the initial and long-term treatment of venous thromboembolism. Thrombosis Research, 2015, 135, 311-317.	1.7	18
36	Platelet count and outcome in patients with acute venous thromboembolism. Thrombosis and Haemostasis, 2013, 110, 1025-1034.	3.4	17

#	Article	IF	CITATIONS
37	D-dimer levels and 90-day outcome in patients with acute pulmonary embolism with or without cancer. Thrombosis Research, 2014, 133, 384-389.	1.7	16
38	Subsequent arterial ischemic events in patients receiving anticoagulant therapy for venous thromboembolism. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2015, 3, 135-141.e1.	1.6	16
39	Analysis of environmental risk factors for pulmonary embolism: A case-crossover study (2001–2013). European Journal of Internal Medicine, 2016, 31, 55-61.	2.2	16
40	Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism. PLoS ONE, 2018, 13, e0194673.	2.5	16
41	Lung cancer mortality in Spain: estimating the future burden to the year 2028. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1117-1121.	1.2	15
42	Analysis of noncatheter-associated upper extremity deep venous thrombosis from the RIETE registry. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2017, 5, 18-24.e1.	1.6	15
43	Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism. American Journal of Medicine, 2018, 131, 430-437.	1.5	15
44	Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism. TH Open, 2019, 03, e67-e76.	1.4	15
45	Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis. BMJ Open, 2017, 7, e015562.	1.9	14
46	Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2018, 45, 360-368.	2.1	14
47	Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism. Chest, 2022, 161, 524-534.	0.8	14
48	Clinical outcome in patients with venous thromboembolism receiving concomitant anticoagulant and antiplatelet therapy. European Journal of Internal Medicine, 2014, 25, 821-825.	2.2	13
49	Systolic blood pressure and mortality in acute symptomatic pulmonary embolism. International Journal of Cardiology, 2020, 302, 157-163.	1.7	13
50	Gender differences in lung cancer mortality trends in Andalusia 1975–2008: a joinpoint regression analysis. Medical Oncology, 2012, 29, 1593-1598.	2.5	12
51	Validación de 2 escalas clÃnicas pronósticas en pacientes con tromboembolia pulmonar aguda sintomática. Archivos De Bronconeumologia, 2013, 49, 427-431.	0.8	12
52	Statin and all-cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry. European Journal of Internal Medicine, 2019, 68, 30-35.	2.2	12
53	Screening for Occult Cancer in Patients with Venous Thromboembolism: Past, Present, and Future. Hamostaseologie, 2020, 40, 270-279.	1.9	12
54	Comparative clinical prognosis of massive and nonâ€massive pulmonary embolism: A registryâ€based cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 408-416.	3.8	12

#	Article	IF	CITATIONS
55	Consenso multidisciplinar para el manejo de la tromboembolia de pulmón. Archivos De Bronconeumologia, 2022, 58, 246-254.	0.8	12
56	Association between Radiotherapy and Risk of Cancer Associated Venous Thromboembolism: A Sub-Analysis of the COMPASSâ€"CAT Study. Cancers, 2021, 13, 1033.	3.7	12
57	Factors Associated with elevated Pulmonary Arterial Pressure Levels on the Echocardiographic Assessment in Patients with Prior Pulmonary Embolism. Thrombosis Research, 2013, 131, e191-e195.	1.7	11
58	Rivaroxaban for the treatment of venous thromboembolism. A "real-life―perspective in 103 patients. Thrombosis Research, 2014, 134, 617-621.	1.7	11
59	Noninvasive ventilation during the weaning process in chronically critically ill patients. ERJ Open Research, 2016, 2, 00061-2016.	2.6	11
60	Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism. European Respiratory Journal, 2022, 59, 2100412.	6.7	11
61	Venous thromboembolism in young adults: Findings from the RIETE registry. European Journal of Internal Medicine, 2019, 63, 27-33.	2.2	10
62	Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2020, 8, 353-359.e1.	1.6	10
63	Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 168-178.	2.3	10
64	A Prognostic Score to Identify Low-risk Outpatients with Acute Deep Vein Thrombosis in the Lower Limbs. American Journal of Medicine, 2015, 128, 90.e9-90.e15.	1.5	9
65	Lights and shadows of non-invasive mechanical ventilation for chronic obstructive pulmonary disease (COPD) exacerbations. Annals of Thoracic Medicine, 2015, 10, 87.	1.8	9
66	Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation. American Journal of Medicine, 2017, 130, 482.e1-482.e9.	1.5	9
67	Mortality after pulmonary embolism in patients with diabetes. Findings from the RIETE registry. European Journal of Internal Medicine, 2019, 59, 46-52.	2.2	9
68	The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease. Clinical Cardiology, 2019, 42, 346-351.	1.8	9
69	Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism. Internal and Emergency Medicine, 2019, 14, 1101-1112.	2.0	9
70	Bronchoalveolar Lavage Findings in Patients With Diffuse Interstitial Lung Disease: Prospective Study of a Cohort of 562 Patients. Archivos De Bronconeumologia, 2009, 45, 115-121.	0.8	8
71	Effects of long-term anticoagulant therapy on levels of circulating microparticles in patients with deep venous thrombosis. Blood Coagulation and Fibrinolysis, 2011, 22, 628-629.	1.0	8
72	A prognostic score to identify lowâ€risk outpatients with acute deep vein thrombosis in the upper extremity. Journal of Thrombosis and Haemostasis, 2015, 13, 1274-1278.	3.8	8

#	Article	IF	CITATIONS
73	Relationship between type of unprovoked venous thromboembolism and cancer location: An individual patient data meta-analysis. Thrombosis Research, 2019, 176, 79-84.	1.7	8
74	Dâ€dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the <scp>RIETE</scp> registry. Journal of Internal Medicine, 2020, 287, 32-41.	6.0	8
75	Role of a clinical prediction score in a chronic thromboembolic pulmonary hypertension rule-out strategy. European Respiratory Journal, 2018, 51, 1702576.	6.7	7
76	Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous Thromboembolism. TH Open, 2018, 02, e210-e217.	1.4	7
77	Timing and characteristics of venous thromboembolism after noncancer surgery. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2021, 9, 859-867.e2.	1.6	7
78	Differential biomarker profiles between unprovoked venous thromboembolism and cancer. Annals of Medicine, 2020, 52, 310-320.	3.8	7
79	High correlation between 2 flow cytometry platforms in the microparticles analysis using a new calibrated beads strategy. Translational Research, 2015, 166, 733-739.	5.0	6
80	Sex Differences in Patients With Occult Cancer After Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 489-495.	1.7	6
81	Venous Thromboembolism in Patients With Autoimmune Disorders: Findings From the RIETE Registry. Angiology, 2020, 71, 131-138.	1.8	6
82	Tromboembolismo pulmonar y embolia parad \tilde{A}^3 jica concomitante. A prop \tilde{A}^3 sito de un caso. Archivos De Bronconeumologia, 2014, 50, 120-122.	0.8	5
83	The impact of disseminated intravascular coagulation on the outcome of cancer patients with venous thromboembolism. Blood Coagulation and Fibrinolysis, 2015, 26, 709-711.	1.0	5
84	Venous thromboembolism in patients immobilised at home. European Respiratory Journal, 2015, 45, 1728-1731.	6.7	5
85	Extended treatment of cancer-associated thrombosis. Thrombosis Research, 2019, 181, 1-9.	1.7	5
86	Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years. Scientific Reports, 2019, 9, 20064.	3.3	5
87	Prognostic Significance of Incidental Deep Vein Thrombosis in Patients with Cancer Presenting with Incidental Pulmonary Embolism. Cancers, 2020, 12, 2267.	3.7	5
88	Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores. TH Open, 2021, 05, e319-e328.	1.4	5
89	Hipertensi \tilde{A}^3 n pulmonar tromboemb \tilde{A}^3 lica cr \tilde{A}^3 nica debida a trombosis venosa profunda de miembro superior por s \tilde{A} ndrome del desfiladero tor \tilde{A} ¡cico. Archivos De Bronconeumologia, 2012, 48, 61-63.	0.8	4
90	Pulmonary Embolism and Concomitant Paradoxical Embolism. A Case Report. Archivos De Bronconeumologia, 2014, 50, 120-122.	0.8	4

#	Article	IF	CITATIONS
91	Screening for occult cancer: where are we in 2020?. Thrombosis Research, 2020, 191, S12-S16.	1.7	4
92	Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism. Journal of the American Heart Association, 2021, 10, e021467.	3.7	4
93	Riesgo de recurrencia tras retirada de la anticoagulaci \tilde{A}^3 n en pacientes con enfermedad tromboemb \tilde{A}^3 lica venosa no provocada: validaci \tilde{A}^3 n externa del nomograma de Viena y del modelo predictivo DASH. Archivos De Bronconeumologia, 2019, 55, 619-626.	0.8	4
94	PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19. Viruses, 2021, 13, 2128.	3.3	4
95	[Translated article] Multidisciplinary consensus for the management of pulmonary thromboembolism. Archivos De Bronconeumologia, 2022, 58, T246-T254.	0.8	4
96	Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study). Cancers, 2022, 14, 2771.	3.7	4
97	Dyslipidemia as a long-term marker for survival in pulmonary embolism. Revista Portuguesa De Pneumologia, 2011, 17, 205-210.	0.7	3
98	Clinical Characteristics and Prognosis of Pulmonary Embolism Caused by Economy Class Syndrome. Archivos De Bronconeumologia, 2017, 53, 495-500.	0.8	3
99	Outcomes beyond the Third Month of Anticoagulation in Patients Aged >75 Years with a First Episode of Unprovoked Venous Thromboembolism. TH Open, 2018, 02, e428-e436.	1.4	3
100	Intermittent pneumatic compression plus pharmacological thromboprophylaxis to prevent deep vein thrombosis. Journal of Thoracic Disease, 2019, 11, 1731-1733.	1.4	3
101	Correlation between short-term air pollution exposure and unprovoked lung embolism. Prospective observational (Contamina-TEP Group). Thrombosis Research, 2020, 192, 134-140.	1.7	3
102	Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism: Rationale and design of the PLATO-VTE study. Thrombosis Update, 2021, 2, 100030.	0.9	3
103	Case-Control Analysis of the Impact of Anemia on Quality of Life in Patients with Cancer: A Qca Study Analysis. Cancers, 2021, 13, 2517.	3.7	3
104	Right Atrium Mass in a 28-Year-Old Patient with Pulmonary Embolism Taking Contraceptives. Journal of Atherosclerosis and Thrombosis, 2011, 18, 829-832.	2.0	3
105	Venous thromboembolism in amyotrophic lateral sclerosis. A prospective quasi-experimental study. Thrombosis Research, 2022, 211, 81-84.	1.7	3
106	Updated Guidelines for the Treatment of Pulmonary Sarcoidosis. , 0, , .		2
107	Hipertensión pulmonar tromboembólica crónica. Cardiocore, 2013, 48, 60-64.	0.0	2
108	Clinically relevant bleeding and thrombotic events in non-cirrhotic splanchnic vein thrombosis. Long-term follow up. Thrombosis Research, 2017, 154, 55-58.	1.7	2

#	Article	lF	CITATIONS
109	Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry. Journal of Thrombosis and Thrombolysis, 2018, 46, 551-558.	2.1	2
110	Adjusted D-dimer cutoff levels to rule out pulmonary embolism in patients hospitalized for COPD exacerbation: results from the SLICE trial. Thrombosis Journal, 2022, 20, 10.	2.1	2
111	Effect of Prognostic Guided Management of Patients With Acute Pulmonary Embolism According to the European Society of Cardiology Risk Stratification Model. Frontiers in Cardiovascular Medicine, 2022, 9, 872115.	2.4	2
112	ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly. ERJ Open Research, 2022, 8, 00665-2021.	2.6	2
113	Chronic Thromboembolic Pulmonary Hypertension Due to Upper-Extremity Deep Vein Thrombosis Caused Thoracic Outlet Syndrome. Archivos De Bronconeumologia, 2012, 48, 61-63.	0.8	1
114	CO211: Prevalence of Metabolic Syndrome and All-Causes Mortality in Patients with Acute Symptomatic Venous Thromboembolism (VTE). Thrombosis Research, 2014, 133, S62.	1.7	1
115	Corrigendum to â€~Rivaroxaban for the treatment of venous thromboembolism. A "real-life―perspective in 103 patients' [Thrombosis Research 134 (2014) 617–621]. Thrombosis Research, 2015, 136, 182.	1.7	1
116	Response. Chest, 2017, 151, 728-729.	0.8	1
117	CaracterÃsticas clÃnicas y pronóstico de la tromboembolia pulmonar secundaria al sÃndrome de clase turista. Archivos De Bronconeumologia, 2017, 53, 495-500.	0.8	1
118	Enfermedad tromboemb \tilde{A}^3 lica venosa y c \tilde{A}_i ncer: un reto para los cl \tilde{A}_n icos. Archivos De Bronconeumologia, 2018, 54, 359-360.	0.8	1
119	Towards a precision medicine in venous thromboembolism associated to lung cancer. Journal of Thoracic Disease, 2018, 10, S3064-S3066.	1.4	1
120	Thromboprophylaxis after renal transplantation and patient risk stratification: The case of mTOR inhibitors. Thrombosis Research, 2020, 195, 100-102.	1.7	1
121	Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962093120.	1.7	1
122	Deep vein thrombosis and brain metastases. Case report and systematic review. Thrombosis Research, 2021, 197, 195-201.	1.7	1
123	Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism. Internal and Emergency Medicine, 2021, , 1.	2.0	1
124	Lowâ€dose apixaban in extended treatment of cancerâ€associated thrombosis: Less is more?. Journal of Thrombosis and Haemostasis, 2022, 20, 1070-1072.	3.8	1
125	Clinical Manifestations of Sarcoidosis. , 2013, , .		0
126	C0246: Quality of Life in Acute Symptomatic Pulmonary Embolism and Low-Risk Prognosis. Thrombosis Research, 2014, 133, S119.	1.7	0

#	Article	IF	Citations
127	Discharge Planning of Neuromuscular Patients with Noninvasive Mechanical Ventilation After Difficult Weaning from Invasive Mechanical Ventilation: From ICU to Home Care., 2016,, 361-369.		O
128	Calidad de vida en pacientes diagnosticados de embolia de pulmón aguda sintomática. Revista Clinica Espanola, 2017, 217, 121-122.	0.6	0
129	Venous Thromboembolic Disease and Cancer: A Challenge for Clinicians. Archivos De Bronconeumologia, 2018, 54, 359-360.	0.8	0
130	Reply to comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis'. British Journal of Cancer, 2019, 120, 473-474.	6.4	0
131	Trombosis sintomática de la vena ácigos: caso clÃnico y revisión de la literatura. Archivos De Bronconeumologia, 2021, 57, 506-509.	0.8	0
132	Multidisciplinary consensus for the management of pulmonary thromboembolism. Archivos De Bronconeumologia, 2021, , .	0.8	0
133	Comment on "Severity of pulmonary embolism at initial diagnosis and long-term clinical outcomes: From the COMMAND VTE Registry― International Journal of Cardiology, 2021, 344, 190-191.	1.7	0
134	Hemorragia digestiva baja asociada a celecoxib. Anales De Medicina Interna, 2003, 20, .	0.1	0
135	Respiratory intermediate care units: Noninvasive ventilation for severe acidotic patients. , 2015, , .		0
136	Long-term low molecular weight heparin treatment in cancer associated venous thromboembolism patients. , $2015, \ldots$		0
137	Factors associated with mortality and survival in venous thromboembolism and hidden or concurrent cancer. , $2015, , .$		0
138	Treatment of venous thromboembolism in cancer patients with tinzaparin beyond 6 months. TiCAT study. , $2016, , .$		0
139	Occult cancer in patients with acute venous thromboembolism: Why, when and where to investigate. , 2016, , .		0
140	Unusual site thrombosis: splanchnic vein thrombosis, management in noncirrothic. , 2016, , .		0
141	Search predictive factors of recurrence in venous thromboembolic disease associated with cancer after withdrawal of the anticoagulation. HISPALIS study. , 2016, , .		0
142	Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin. , 2019, , .		0
143	Venous thromboembolism in solid-organ transplant recipients: findings from the RIETE registry. , 2020, , .		0
144	Major bleeding in patients with pulmonary embolism presenting with syncope. European Journal of Clinical Investigation, 2022, , e13774.	3.4	0